Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).

Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.

Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.

Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.

Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-

Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children

Phase 4
Completed
Conditions
First Posted Date
2008-11-13
Last Posted Date
2008-11-13
Lead Sponsor
Stony Brook University
Target Recruit Count
24
Registration Number
NCT00790075
Locations
🇺🇸

StonyBrook University Hospital (StonyBrook University School of Medicine), StonyBrook, New York, United States

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2008-09-03
Last Posted Date
2020-01-06
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
5
Registration Number
NCT00746252
Locations
🇺🇸

University of Maryland, School of Medicine, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Baltimore, Maryland, United States

Actigraphic Analysis of Treatment Response

First Posted Date
2008-07-28
Last Posted Date
2015-08-18
Lead Sponsor
Child Psychopharmacology Institute
Target Recruit Count
1
Registration Number
NCT00723580
Locations
🇺🇸

Child Psychopharmacology Institute, Fargo, North Dakota, United States

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

First Posted Date
2008-07-25
Last Posted Date
2010-06-29
Lead Sponsor
BioLineRx, Ltd.
Target Recruit Count
220
Registration Number
NCT00722176
Locations
🇺🇸

University of California, Irvine, Irvine, California, United States

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2008-07-09
Last Posted Date
2020-07-28
Lead Sponsor
Kettering Health Network
Target Recruit Count
21
Registration Number
NCT00712270
Locations
🇺🇸

Wallace Kettering Neuroscience Institute, Kettering, Ohio, United States

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

First Posted Date
2008-07-08
Last Posted Date
2022-04-12
Lead Sponsor
Sumitomo Pharma Co., Ltd.
Target Recruit Count
460
Registration Number
NCT00711269
Locations
🇯🇵

Japan: 67 sites, Tokyo, Etc., Japan

🇰🇷

Korea: 14 sites, Seoul, Etc., Korea, Republic of

🇨🇳

Taiwan: 11 sites, Taipei, Etc., Taiwan

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

First Posted Date
2008-06-16
Last Posted Date
2022-02-08
Lead Sponsor
Corcept Therapeutics
Target Recruit Count
76
Registration Number
NCT00698022
Locations
🇮🇳

Dhirubhai Ambani Life Sciences Centre, Mumbai, India

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

First Posted Date
2008-06-10
Last Posted Date
2019-06-12
Lead Sponsor
Forest Laboratories
Target Recruit Count
732
Registration Number
NCT00694707
Locations
🇷🇺

Forest Investigative Site 1, Moscow, Russian Federation

🇺🇦

Forest Investigative Site, Kiev, Ukraine

🇷🇺

Forest Investigative Site 2, St. Petersburg, Russian Federation

and more 1 locations

Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-04-17
Last Posted Date
2010-09-17
Lead Sponsor
AstraZeneca
Target Recruit Count
29
Registration Number
NCT00660595
Locations
🇫🇮

Research Site, Turku, Finland

A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-03-27
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
240
Registration Number
NCT00645515
Locations
🇪🇸

Pfizer Investigational Site, Madrid, Spain

© Copyright 2024. All Rights Reserved by MedPath